QUANTUM X LABS INC. quarterly report, Q3 FY2018

Virtual Crypto Technologies, Inc. — Q3 2018 Form 10-Q

Reporting period: Three and nine months ended September 30, 2018; filed November 13, 2018. The filing identifies the registrant as Virtual Crypto Technologies, Inc. (formerly Emerald Medical Applications Corp.), not Quantum X Labs Inc.

Business context and reporting period

In 2018, the company shifted from skin-imaging operations to developing cryptocurrency trading software and hardware through its Israeli subsidiary. It ceased its former DermaCompare operations in January; the subsidiary was placed into winding-up proceedings in May. The company describes its NetoBit Trader technology as enabling real-time cryptocurrency transaction confirmation. It reported no revenue in either 2018 or the comparable 2017 periods.

Financial results and position

  • Q3 2018: Revenue was $0; operating expenses were $283,706, including $107,971 of research and development. Net loss was $543,572, or $0.01 per share. In Q3 2017, operating expenses were $30,885 and the company reported net income of $44,115 before discontinued operations.
  • Nine months 2018: Revenue was $0; operating expenses were $2,335,469, including $738,936 of research and development. Net loss was $24,585,177, or $0.44 per share, versus a $1,415,989 net loss in the comparable 2017 period.
  • Unusual finance item: Nine-month net finance expense was $22,249,708, primarily related to changes in convertible-note terms. The company recorded $21,622,897 of finance expense from the transaction and a $22.6 million increase to additional paid-in capital. This substantially amplified the reported loss.
  • Cash flow: Nine-month cash used in continuing operating activities was $1,319,865; financing activities provided $2,041,013, mainly from a $1,940,950 stock-and-warrant offering. Ending cash was $724,107, up from $2,959 at year-end 2017. Investing cash flow was $0.
  • Liquidity and debt: Current assets were $834,354 and current liabilities were $1,406,224, yielding negative working capital of $571,870. Current liabilities included $683,917 of short-term convertible notes and $486,045 of liabilities held for sale. Total liabilities were $1,406,224; total assets were $834,354. Management said available funds were expected to support operations through June 2019, but also stated that additional financing was necessary and no committed external funding source existed.
  • Equity: Common shares outstanding increased from 22,543,008 at December 31, 2017 to 63,727,843 at September 30, 2018. The company also issued substantial warrants, creating potential further dilution.

Material changes, outlook and risks

  • The Chiron term sheet contemplated an exclusive distributor for Turkey and Northern Cyprus, subject to a $250,000 appointment fee; the company reported receiving $100,000, recorded as deferred revenue. A Nigeria distribution option could involve a further fee of up to $250,000 if exercised. The filing does not establish that the products were commercially launched or that the distribution arrangements were completed.
  • The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses, negative operating cash flow, limited capital and the need for further financing. Management said it was seeking additional equity or other funding; no assurance of availability was given.
  • Emerald Israel is in winding-up proceedings. Management did not expect excess liquidation proceeds to benefit the company after obligations and the former preferred holders’ potential priority claim. The balance sheet includes $486,045 of liabilities held for sale; the filing also describes former employee claims of less than $96,000, included in current liabilities.
  • Disclosure controls and procedures were deemed ineffective as of September 30, 2018, due to material weaknesses and insufficient resources and personnel. The filing reported no material changes in internal control during the quarter.
  • Other contingencies include a former executive’s Israeli lawsuit seeking $100,000 in damages, which the company said it intended to defend and did not expect to be material. The financial statements are unaudited.

Important facts for investors to verify

  • Whether the reported cash runway through June 2019 was achieved and what financing was subsequently obtained.
  • The accounting, valuation and settlement terms behind the large convertible-note modification expense, and the remaining debt obligations.
  • Commercial readiness of NetoBit products and the status, enforceability and payment terms of the Chiron arrangements.
  • Final liabilities and any recoveries from Emerald Israel’s liquidation, including the treatment of employee and former preferred-holder claims.
  • Potential dilution from outstanding warrants and any subsequent share issuances, and whether the disclosed control weaknesses were remediated.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.